Participated · Series B · Mar 2026

N.B.Medical focuses on creating next-generation medical devices for the treatment of cerebrovascular diseases. Its core technology blends hardware innovation—such as anti-thrombotic coating and high-precision intravascular engineering—with an in-house digital transformation and AI-powered computer modeling & simulation (CMS) platform that streamlines regulatory-compliant device development. The company aims to raise the standard of care by accelerating clinical trial readiness and ultimately deploying its products in both Japanese and overseas hospitals. Founded in October 2021 by CEO Kazuya Shobayashi, the team collaborates with institutions like UCLA and AIST to enhance R&D. Recent funding activity shows strong investor confidence: the Series B round now totals ¥3.35 billion, which includes a ¥500 million NEDO DTSU grant. Capital will be deployed to speed R&D, refine the CMS platform, and prepare for global commercialization. No revenue or user metrics have been disclosed, reflecting the company’s pre-commercial stage focus on product development.

Participated · Equity · Aug 2025

Stan operates a social platform designed for gaming creators, publishers and their communities, offering tools that blend social interaction with monetisation features for streamers and influencers. The company’s app has been downloaded more than 30 million times, with notable penetration in India’s tier-II and tier-III cities. Management plans to invest heavily in AI-driven personalisation, expanded creator monetisation toolsets and deeper publisher integrations to strengthen user engagement and revenue opportunities. Future strategy also includes scaling the platform into other mobile-first international markets. The product vision emphasises building dynamic ecosystems where gamers, creators and developers can co-create shared worlds. Financially, Stan has attracted $10.5 million in Series A funding to date, signalling strong investor confidence in its growth trajectory.

Led · Series B · Apr 2024

Kamereo is an online marketplace that enables farmers and food and beverage businesses to trade and source fresh supplies. The company is led by CEO and Founder Taku Tanaka. Its platform aims to help users optimize purchasing and sourcing processes. Kamereo raised $2.1M in funding to support its growth. The company plans to use the proceeds to expand operations and broaden its business reach across Vietnam and abroad. Its immediate international expansion target is Cambodia. Kamereo is a B2B platform with its own warehouse and last-mile delivery network that negotiates with suppliers, processes orders, and fulfills deliveries for restaurants and other F&B businesses. Founded in 2018 and based in Ho Chi Minh City, it works with about 15 farmers and serves more than 400 active customers, from family-owned restaurants to chains. The company has about 100 employees and reports 15% month-over-month growth over the last 12 months despite COVID-19 disruptions. Most last-mile deliveries are done by motorbikes; Kamereo operates its own logistics because it says this is cheaper than third-party providers and plans to expand a micro-warehouse network in Ho Chi Minh City to reduce travel distances. Its tech team is building an internal warehouse management, inventory, fulfillment, and last-mile delivery system aimed at minimizing variable costs. The newly raised capital will be used for hiring, building a new warehouse management system, user interface upgrades, and expansion into Hanoi next year. KAMEREO operates a B2B purchasing and sourcing platform that connects restaurants with suppliers in Vietnam. The company focuses on simplifying purchasing and sourcing workflows for restaurant customers. According to an official statement, KAMEREO raised $500,000 in a seed round. The seed funding came from Japan’s Genesia Ventures and homegrown VC Velocity Ventures Vietnam (VVV). The article did not disclose operating metrics, prior funding rounds, or a founding year. No specific product road map or future plans were detailed in the article.

Participated · Series C · Jul 2022

Metcela is a clinical-stage biotechnology company based in Kanagawa, Japan, developing first-in-class autologous cell therapies targeting serious cardiovascular diseases. Established in 2016, the company focuses on fibroblast and stem cell–based therapies for chronic diseases with limited treatment options. Metcela is advancing MTC001, a combination product of autologous cardiac cells (VCAM-1-positive Cardiac Fibroblast, VCF) paired with a novel catheter delivery system for chronic heart failure patients. The company recently closed a $14M Series C financing to support its plans. Proceeds will be used to prepare for commercialization by establishing manufacturing infrastructure, to strengthen new pipeline development capabilities, and to reinforce R&D by expanding research facilities. Metcela is positioning to move its clinical programs toward commercialization while expanding its research and manufacturing capacity. Metcela is a clinical-stage biotech founded in 2016 in Kanagawa, Japan, focused on developing fibroblast-based therapies for chronic diseases with limited options. Its lead asset, MTC001, is a VCAM-1-positive Cardiac Fibroblast (VCF) cell therapy that re-established a favorable microenvironment and repaired damaged heart tissues in preclinical studies. MTC001 uses a simple hospital-to-manufacturing-site-to-hospital workflow; VCF is collected from a cardiac biopsy in a minimally invasive manner. The company says VCF has significant manufacturing and safety advantages over alternative approaches. The $12.7M Series B enables Metcela to initiate Phase I clinical trials in Japan. Metcela intends to use the funds to grow its team and expand its portfolio. Metcela is a clinical-stage biotechnology company focused on developing fibroblast-based cell therapies. Its lead product, MTC001, is a fibroblast-based therapy intended to treat chronic heart failure. Through preclinical research the company identified VCAM-1-positive cardiac fibroblasts (VCFs) that stimulate cardiomyocyte proliferation and improve cardiac function via lymphangiogenesis. Metcela plans to accelerate clinical development of MTC001 and initiate a Phase I clinical trial. The company closed a ¥430m (≈$4m) Series B to support these efforts. Metcela is led by Co-CEOs Takahiro Iwamiya and Kenichi Nogami and recently appointed Kenji Yamada as an outside director.